ロード中...
Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma
LESSONS LEARNED: Trials dedicated to metastatic uveal melanoma are needed because of the poor prognosis of this rare cancer and because its biology is distinct from that of cutaneous melanoma. Agents targeting the MEK/ERK/MAP kinase pathways are being tested. BACKGROUND. In experimental models, beva...
保存先:
| 出版年: | Oncologist |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
AlphaMed Press
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4786360/ https://ncbi.nlm.nih.gov/pubmed/26911405 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0501 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|